HCV screening in blood donations using RT-PCR in mini-pool:: the experience in Spain after routine use for 2 years

被引:13
作者
Eiras, A
Sauleda, S
Planelles, D
Sedeño, M
Ibarra, A
Vesga, MA
Franco, E
Montoro, JA
Hernández, JM
Villaescusa, RG
机构
[1] Ctr Transfus Galicia, Santiago De Compostela 15706, Spain
[2] Blood Transfus Ctr Barcelona, Barcelona, Spain
[3] Blood Transfus Ctr Valencian Community, Valencia, Spain
[4] Blood Transfus Ctr Balear Isl, Palma de Mallorca, Spain
[5] Blood Transfus Ctr Basque Country, Galdakao, Spain
关键词
D O I
10.1046/j.1537-2995.2003.00420.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: The aim of this study is to evaluate the feasibility of implementing a commercial HCV RNA RT-PCR screening method and provide data on the prevalence and incidence rates of hepatitis C in Spain. STUDY DESIGN AND METHODS: Five transfusion centers participated in the study, covering 34.1 percent of the country's total number of donations. All the centers evaluated the sensitivity and characteristics of a commercial RT-PCR reagent kit designed for pool testing (Cobas AmpliScreen HCV v2.0), for which serial dilutions of HCV WHO International Standard 96/790 and preseroconversion samples were used. The data obtained from this technique, employed routinely from May 1999 to June 2001 in 22- to 48-unit minipools, are presented in this study. RESULTS: An overall 95-percent detection limit was obtained either at 69 IU per mL when 0.2 mL volume of plasma was extracted (used to analyze individual units), or at 20 IU per mL, when viral particles were pelleted from I mL plasma (as used for screening in mini-pool) Three HCV-RNA-positive anti-HCV-negative donations were identified out of 1,015,482 screened donations. One of these had an initially undisclosed risk of HCV sexual transmission and carded a low viral load of 10(4.2) IU per mL HCV RNA. The analysis of first-time (FT) donations during the period of study (21.3% of the total) indicated an average prevalence rate of 2.05 per 10(3) FT donors (of which 1.55/10(3) IFT donors were RNA positive); the residual risk calculated on repeat (RPT) donors was 3.91 per 10(6) donations (serology) or 0.59 per 106 donations (serology + NAT), and the predicted NAT yield estimate was 4.2 per 10(6) FT + RPT donations. CONCLUSIONS: The commercial RT-PCR reagent kit complies with the current European and FDA recommendations on sensitivity and can be easily implemented on a routine basis. The results obtained by the five transfusion centers on the predicted NAT yield (1/302,000 RPT donations or 1/237,000 FT + RPT donations) are very close to the published estimates corresponding to a larger area of our country (1/237,000 RPT donations) and are somewhat higher than, though in line with, the observed NAT yield (1/338,000 FT + RPT donations).
引用
收藏
页码:713 / 720
页数:8
相关论文
共 18 条
[1]   Estimated risk of transfusion-transmitted viral infections in Spain [J].
Alvarez, M ;
Oyonarte, S ;
Rodríguez, PM ;
Hernández, JM .
TRANSFUSION, 2002, 42 (08) :994-998
[2]   The first case of HCV seroconversion in Portugal after the introduction of HCVNAT screening [J].
Araújo, FM ;
Henriques, I ;
Monteiro, F ;
Meireles, E ;
Koch, MC ;
Celeste, R ;
Cunha-Ribeiro, LM .
TRANSFUSION, 2001, 41 (06) :848-849
[3]   The first case of HCV seroconversion after 3 years of HCVNAT screening in Baden-Wurttemberg [J].
Cardoso, MD ;
Koerner, K ;
Kubanek, B .
TRANSFUSION, 2000, 40 (11) :1422-1423
[4]   Mini-pool testing by the polymerase chain reaction for viral nucleic acids: HCV concentration efforts [J].
Cardoso, MD ;
Koerner, K ;
Epple, S ;
Lenz, C ;
Hinz, W ;
Kubanek, B .
VOX SANGUINIS, 1998, 74 (04) :262-262
[5]  
*COMM PROPR MED PR, 1998, INTRO NUCL AC AMPL T
[6]   International application of the incidence rate/window period model [J].
Glynn, SA ;
Kleinman, SH ;
Wright, DJ ;
Busch, MP .
TRANSFUSION, 2002, 42 (08) :966-972
[7]   A novel RT-PCR for reliable and rapid HCV RNA screening of blood donations [J].
Hennig, H ;
Luhm, J ;
Hartwig, D ;
Klüter, H ;
Kirchner, H .
TRANSFUSION, 2001, 41 (09) :1100-1106
[8]   Routine HCVPCR screening of blood donations to identify early HCV infection in blood donors lacking antibodies to HCV [J].
Hitzler, WE ;
Runkel, S .
TRANSFUSION, 2001, 41 (03) :333-337
[9]   Significant closure of the human immunodeficiency virus type 1 and hepatitis C virus preseroconversion detection windows with a transcription-mediated-amplification-driven assay [J].
Kolk, DP ;
Dockter, J ;
Linnen, J ;
Ho-Sing-Loy, M ;
Gillotte-Taylor, K ;
McDonough, SH ;
Mimms, L ;
Giachetti, C .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (05) :1761-1766
[10]   Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: Calibration to international units, enhanced genotype reactivity, and performance characteristics [J].
Lee, SC ;
Antony, A ;
Lee, N ;
Leibow, J ;
Yang, JQ ;
Soviero, S ;
Gutekunst, K ;
Rosenstraus, M .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (11) :4171-4179